LMO2 is an intrinsically disordered transcription factor activated in T cell leukaemia that is difficult to target. It forms part of a multiprotein complex that has bipartite DNA binding through ...

Trailhead Biosystems expands iPSC-derived portfolio with TrailBio Hematopoietic Progenitor Cells: Beachwood, Ohio Wednesday, August 6, 2025, 16:00 Hrs [IST] Trailhead Biosystems, ...

Fresenius Kabi has licensed rights from Polpharma Biologics to commercialize the vedolizumab biosimilar candidate PB016 globally—except in the ...

ZUG, Switzerland and BOSTON, Aug. 04, 2025 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious ...

Researchers at Kyoto University have discovered that an immune molecule found only in primates, called IGFL2, plays a key role in regulating ...

Novel allogeneic stem cells and differentiated iPSCs are providing more physiologically relevant disease models.

These soluble protein agonists can replicate Notch activation in suspension culture, opening the door to scalable T-cell therapies.

Tumors of the pancreas seldom cause symptoms in their early stages. This means that in many cases, they are not diagnosed until late, when the chances of successful treatment are poor. A new ...

Women and people assigned female at birth can't get prostate cancer, but they can get a similar type, called Skene's gland ...

New insights into how β-cell subtypes influence diabetes risk and how maternal diet, epigenetics, and stem cell therapies may ...

Despite challenges in studying allergen-specific CD4+ T cells in food allergy, targeted approaches signal progress while ...

An expert discusses the clinical presentation and diagnosis of immune thrombocytopenic purpura (ITP), emphasizing that ...